- Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Kezar Life Sciences Inc at Wells Fargo Healthcare Conference TranscriptSep 07, 2023
- Kezar Life Sciences Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Kezar Life Sciences Inc R&D Day TranscriptMar 15, 2023
- Alpine Immune Sciences Inc and Kezar Life Sciences Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Kezar Life Sciences Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Kezar Life Sciences Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Kezar Life Sciences Inc Topline Results from the MISSION Phase 2 Clinical Trial Evaluating Zetomipzomib - Corporate Call TranscriptJun 27, 2022
- Kezar Life Sciences Inc Annual Shareholders Meeting TranscriptJun 25, 2021
- Kezar Life Sciences Inc At TMA's International Annual Patient Conference TranscriptSep 22, 2020
- Q2 2020 Kezar Life Sciences Inc Earnings Call TranscriptAug 05, 2020$4.72 (+1.83%)Earnings
- Kezar Life Sciences Inc At MSU: Rare Disease Day Presentation TranscriptApr 15, 2020
- Kezar Life Sciences Inc At PRESIDIO Clinical Trial of KZR-616 TranscriptMar 05, 2020
Kezar Life Sciences Inc R&D Day Transcript
Welcome to Kezar's Life Sciences 2023 Research and Development Day. Today's presentation will be followed by a question-and-answer session.
During the course of this call, Kezar will be making forward-looking statements based on current expectations. These forward-looking statements are subject to a number of risks and uncertainties, and actual results may differ materially from those described.
We encourage you to review the risk factors in our most recent Form 10-K filed with the US Securities and Exchange Commission and available on our website. All statements on this call are made as of today based on information currently available to us. Except as required by law, we disclaim any obligation to update such statements even if our views change.
With that, I would now like to hand the call over to John Fowler, Chief Executive Officer and Co-Founder of Kezar Life Sciences. Go ahead, John.
Thank you, operator, for the introduction, and really thank you to everyone who's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)